Erschienen in:
01.03.2014 | Gonadal Physiology and Disease
Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Polycystic Ovary Syndrome Risk: A Meta Analysis
verfasst von:
Ying Liu, Mei-Guo Sun, Rong Jiang, Rui Ding, Zhen Che, Yan-Yan Chen, Ci-Jiang Yao, Xiao-Xia Zhu, Ji-Yu Cao
Erschienen in:
Journal of Assisted Reproduction and Genetics
|
Ausgabe 3/2014
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Several studies have reported that excessive amounts of plasminogen activator inhibitor-1(PAI-1) might increase the incidence of polycystic ovary syndrome(PCOS), but so far the published results were inconsistent. The aim of this study was to further investigate the association between PAI-1 gene polymorphism and the susceptibility to PCOS by performing a meta-analysis.
Methods
A comprehensive literature search for relevant studies was conducted on google scholar, PubMed, the Chinese National Knowledge Infrastructure (CNKI) and the Chinese Biomedical Literature Database (CBM). This meta-analysis was performed using the STATA 11.0 software and the pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated.
Results
Ten case–control studies were included in this meta-analysis with a total of 2,079 cases and 1,556 controls. The results showed that PAI-1 -675 4G/5G polymorphism may increase the risk of PCOS, especially among Asian populations. However, there was no statistically significant association between the polymorphism and PCOS risk in Caucasians.
Conclusion
Our meta-analysis suggests that PAI-1 -675 4G/5G polymorphism may contribute to increasing susceptibility to PCOS in Asians. Detection of the PAI-1 gene polymorphism might be a promising biomarker for the susceptibility of PCOS.